Clinical Evaluation of the OrthoPAT Advance System

This study is intended to provide additional performance data of the OrthoPAT Advance in routine orthopedic surgery.

Study Overview

• Status: Completed
• Conditions: Transmission, Blood, Recipient/Donor
• Intervention / Treatment: Device: OrthoPat Advance

Detailed Description

The OrthoPAT Advance system is being developed by Haemonetics to change the user interface, especially for adding calculations for Estimating Blood Loss- (EBL). The OrthoPAT® serves as the predicate device. The following items will be changed in the OrthoPAT Advance system compared to OrthoPAT:

• Software & User Interface - ability to enter irrigant and anti-coagulant volumes and allow Estimated Blood Loss (EBL) calculation to be made by OrthoPAT Advance.

• Hardware -

  • Redesign of reservoir and filter to process blood earlier by reducing hold-up volume and improve fluid visualization in reservoir.
  • Extended battery life.

It is not intended to validate the major changes in the OrthoPAT Advance device (reservoir / filter and EBL), which will be conducted as lab based tests. The correct functioning of the reservoir / filter and EBL changes will be confirmed in the clinical setting in this study. However the most rigorous challenge to the filter will be by presenting the worst case media and this can only be controlled in the laboratory.

• Study Type: Observational
• Enrollment (Actual): 84

Contacts and Locations

Study Locations

• United States
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15213
      • University of Pittsburgh Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Subjects scheduled for hysterectomy or orthopediac procedures.

Description

Inclusion Criteria:

• Male or female over the age of 18 years
• Subject is scheduled for a total knee/hip replacement/ revision or a hysterectomy.
• Subjects determined eligible per site standard of care for use of intra- and post-operative use of cell salvage device

Exclusion Criteria:

For subjects where product is transfused

• Subject is undergoing a trauma procedure where there is a possibility of contamination from an open wound.
• Patient is diagnosed with sepsis.
• Patient is diagnosed with sickle-cell anemia.
• Malignant cells may be mixed with blood salvaged from the surgical field.
• Prostatic or amniotic fluid is mixed with blood salvaged from the surgical field.
• Blood salvaged from the surgical field may be contaminated from an active infection at wound/drain site.
• Blood salvaged from the surgical field contains topical hemostatic agents, anti-bacterial agents, or wound irrigants not intended for parenteral use.

For all subjects:

• Subject is undergoing a procedure which involves high, rapid blood loss such as liver transplants, certain cardiovascular procedures, and trauma procedures where blood loss is high (per Investigators judgment).
• Any procedure terminated prior to completion by subject request, operator decision or error, or device error.
• Any subject with which at least 200mL of filtered blood or 1 full disc is not available for processing and data collection within the study.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Investigational Device; The 510k cleared OrthoPAT Advance will be used in this standard of care arm.	Device: OrthoPat Advance; The device will be used initially in hysterectomy procedures. After a confirmation of product quality, the device will be used in routine orthopedic procedures.
Control Group; The commercially available OrthoPAT will be used in this arm. This is an observational trial and there is no intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Washed RBC Hematocrit	The Hematocrit of the RBC shall be > 50%.	< 4 hours

Collaborators and Investigators

• Sponsor: Haemonetics Corporation
• Investigators: Principal Investigator: Jonathan Waters, MD, University of Pittsburgh Medial Center

Study record dates

Study Major Dates

• Study Start: December 1, 2012
• Primary Completion (Actual): August 1, 2013
• Study Completion (Actual): August 1, 2013

Study Registration Dates

• First Submitted: November 26, 2012
• First Submitted That Met QC Criteria: December 20, 2012
• First Posted (Estimate): December 28, 2012

Study Record Updates

• Last Update Posted (Estimate): November 20, 2013
• Last Update Submitted That Met QC Criteria: September 17, 2013
• Last Verified: September 1, 2013

More Information

Terms related to this study

• Other Study ID Numbers: TP-CLN-100257